Deucravacitinib Shows Significant Efficacy and Safety in Phase 3b/4 Trial for Moderate to Severe Scalp Psoriasis Dermatology Times Source link
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, Melinda Gooderham, MSc, MD, FRCPC, presented late-breaking data on the long-term safety and efficacy of delgocitinib for moderate to severe chronic hand eczema (CHE).1 Patients who completed 16 weeks of treatment in DELTA 1 and DELTA 2 were then treated in […]
Topical phosphodiesterase (PF) 4 inhibitor-07038124 treatment of atopic dermatitis (AD) and plaque psoriasis is both efficacious and well-tolerated among patients, according to recent findings.1 The findings were the result of new research conducted to expand upon existing topical medication options for patients with mild-to-moderate AD or psoriasis, especially given the negative systemic adverse events often […]
Another JAK Inhibitor Shows Efficacy for Atopic Dermatitis in a … Medscape Source link